Peptide News Digest

#Drug-Prices

3 stories

Industry · View digest

CVS Health: Employers Would Break Even on GLP-1 Drugs Priced Below $350 a Month, Aetna Claims Show

Reuters reported that a CVS analysis of Aetna claims linked GLP-1 use to 10% to 12% fewer emergency room visits in the first and second years and, among about 4,000 people still on treatment after three years, 34% to 42% fewer hospitalizations. Over three years, plan sponsors saved $9,400 per person on medical bills but spent $13,300 more on prescriptions, a net cost of $3,900 at current prices. Chief medical officer Amy Compton-Phillips said drugmakers' direct-to-consumer prices, about $299 for Zepbound and $349 for Wegovy, suggest they could still profit below $350.

Regulatory · View digest

Koreans Plan Day Trips to Japan for Cheaper Mounjaro After Seoul Eases Personal Import Rules

The Korea Herald reported that, after Korea began allowing up to a three-month supply of medicines bought legally abroad, one forum user estimated that a Fukuoka day trip with three months of 5 mg Mounjaro would cost about 700,000 won ($520), against more than 1 million won at home. Customs caught 5,030 unauthorized imports of drugs such as Mounjaro and Wegovy in the first eight months of 2026, more than four times the 1,189 cases in all of 2025.

Regulatory · View digest

NPR: North Dakota Joins 29 States Capping Insulin Costs at $25 a Month After Families Testified in Bismarck

NPR and KFF Health News reported that North Dakota's Republican-majority legislature passed a $25-a-month cap on what patients in state-regulated plans pay for insulin. Insurers and the state chamber of commerce opposed it, warning of higher premiums. Average yearly out-of-pocket insulin costs for privately insured patients fell from $470 in 2018 to $220 in 2025, but state caps do not reach most plans from larger employers, which are typically regulated by the federal government.